RDEM – Patient Worthy

Patient Dosing Begins in VIITAL Study of EB-101, a Treatment for Recessive Dystrophic Epidermolysis Bullosa

Post author:Kendall Mason
Post published:March 19, 2020
Post category:Dystrophic epidermolysis bullosa

The first patient has been dosed in the third phase of the VIITAL study, which is intended to evaluate the effectiveness of EB-101. This medication is a gene-corrected cell therapy…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More